These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 19917388)

  • 1. Administration of dalteparin based on the activated clotting time for prophylaxis of hepatic vessel thrombosis in living donor liver transplantation.
    Uchikawa Y; Ikegami T; Masuda Y; Ohno Y; Mita A; Urata K; Nakazawa Y; Terada M; Miyagawa S
    Transplant Proc; 2009 Nov; 41(9):3784-90. PubMed ID: 19917388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coagulation and fibrinolytic profiles and appropriate use of heparin after living-donor liver transplantation.
    Kaneko J; Sugawara Y; Tamura S; Togashi J; Matsui Y; Akamatsu N; Kishi Y; Makuuchi M
    Clin Transplant; 2005 Dec; 19(6):804-9. PubMed ID: 16313329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
    Cavusoglu E; Lakhani M; Marmur JD
    J Invasive Cardiol; 2005 Aug; 17(8):416-21. PubMed ID: 16079447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Feit A; Battala VR; Cavusoglu E
    J Invasive Cardiol; 2008 Jul; 20(7):323-7. PubMed ID: 18599887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
    Frank RD; Brandenburg VM; Lanzmich R; Floege J
    Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for early hemorrhagic and thrombotic complications after kidney transplantation.
    Pawlicki J; Cierpka L; Król R; Ziaja J
    Transplant Proc; 2011 Oct; 43(8):3013-7. PubMed ID: 21996213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfusion requirements during cadaveric and living donor pediatric liver transplantation.
    Ulukaya S; Acar L; Ayanoglu HO
    Pediatr Transplant; 2005 Jun; 9(3):332-7. PubMed ID: 15910390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragmin (LMWH) vs heparin for anticoagulation during in vitro recycling of human blood in cardiopulmonary bypass circuits: dose-dependence and mechanisms of clotting.
    Bagge L; Holmer E; Wahlberg T; Nyström SO; Tydén H
    Blood Coagul Fibrinolysis; 1994 Apr; 5(2):273-80. PubMed ID: 8054461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass.
    Avidan MS; Levy JH; van Aken H; Feneck RO; Latimer RD; Ott E; Martin E; Birnbaum DE; Bonfiglio LJ; Kajdasz DK; Despotis GJ
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):107-13. PubMed ID: 15999048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial.
    Abou-Nassar K; Kovacs MJ; Kahn SR; Wells P; Doucette S; Ramsay T; Clement AM; Khurana R; Mackinnon K; Blostein M; Solymoss S; Kingdom J; Sermer M; Rey E; Rodger M;
    Thromb Haemost; 2007 Jul; 98(1):163-71. PubMed ID: 17598009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.
    Marmur JD; Lakhani M; El Rouby S; Cavusoglu E
    J Invasive Cardiol; 2008 Sep; 20(9):449-54. PubMed ID: 18762674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Living donor liver transplantation: usefulness of hemostatic and prothrombotic screening in potential donors.
    Bustelos R; Ayala R; Martinez J; Martin MA; Toledo T; Grande S; Garfia C; Moreno A; Perez B; Meneu JC; Moreno E; Ribera C
    Transplant Proc; 2009 Nov; 41(9):3791-5. PubMed ID: 19917389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro effect of fresh frozen plasma on the activated coagulation time in patients undergoing cardiopulmonary bypass.
    Barnette RE; Shupak RC; Pontius J; Rao AK
    Anesth Analg; 1988 Jan; 67(1):57-60. PubMed ID: 3257361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration.
    Marmur JD; Anand SX; Bagga RS; Fareed J; Pan CM; Sharma SK; Richard MF
    J Am Coll Cardiol; 2003 Feb; 41(3):394-402. PubMed ID: 12575965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypercoagulability after partial liver resection.
    Bezeaud A; Denninger MH; Dondero F; Saada V; Venisse L; Huisse MG; Belghiti J; Guillin MC
    Thromb Haemost; 2007 Dec; 98(6):1252-6. PubMed ID: 18064322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
    J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro effect of hemodilution on activated clotting time and high-dose thrombin time during cardiopulmonary bypass.
    Huyzen RJ; van Oeveren W; Wei F; Stellingwerf P; Boonstra PW; Gu YJ
    Ann Thorac Surg; 1996 Aug; 62(2):533-7. PubMed ID: 8694618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time.
    Nath FC; Muller DW; Rosenschein U; Ellis SG; Topol EJ
    Can J Cardiol; 1993 Nov; 9(9):797-801. PubMed ID: 8281479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of coagulation parameters in the early period after kidney transplantation.
    Pawlicki J; Cierpka L; Król R; Ziaja J
    Transplant Proc; 2007 Nov; 39(9):2754-5. PubMed ID: 18021978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.